Hepamerz Granules contain L-Ornithine L-Aspartate (3 gm), a compound widely used in the management of hepatic encephalopathy and other liver-related disorders. L-Ornithine L-Aspartate acts by enhancing the urea cycle and ammonia detoxification in the liver, thereby reducing elevated blood ammonia levels commonly observed in patients with liver dysfunction. This mechanism helps to improve mental status and cognitive function in individuals suffering from hepatic encephalopathy. Hepamerz Granules are indicated for use as an adjunctive therapy in chronic liver diseases, including cirrhosis and portal systemic encephalopathy, where hyperammonemia contributes to neurological symptoms. The granulated formulation allows for ease of administration and rapid absorption, facilitating prompt therapeutic effects. Hepamerz is generally well tolerated, with minimal adverse effects reported, making it suitable for both inpatient and outpatient management. It is essential to use Hepamerz under medical supervision, particularly in patients with severe hepatic impairment or concomitant renal dysfunction. Dosage and duration of therapy should be individualized based on clinical response and ammonia levels. Overall, Hepamerz Granules provide an effective therapeutic option to mitigate the neuropsychiatric complications associated with liver insufficiency by targeting the underlying metabolic disturbances.